Open AccessTamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity
Author(s) -
Daniel L. Hertz,
Allison M. Deal,
Joseph G. Ibrahim,
Christine M. Walko,
Karen E. Weck,
Steven Anderson,
Gustav Magrinat,
Oludamilola Olajide,
Susan Moore,
Rachel Raab,
Daniel R. Carrizosa,
Steven Corso,
Garry Schwartz,
Mark J. Graham,
Jeffrey Peppercorn,
David R. Jones,
Zeruesenay Desta,
David A. Flockhart,
James P. Evans,
Howard L. McLeod,
Lisa A. Carey,
William Irvin
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/ymhw-r398
Subject(s) - tamoxifen , cyp2d6 , toxicity , medicine , pharmacology , oncology , cancer , breast cancer , metabolism , cytochrome p450
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom